Participated · Series B · Aug 2020

Aetion delivers real-world evidence through its Aetion Evidence Platform®, which analyzes real-world data to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. The platform is used by the majority of top global biopharma firms, leading payers, and regulatory and HTA agencies to inform decisions about medical products. Led by CEO Carolyn Magill, Aetion serves manufacturers, purchasers, and regulators of medical treatments and technologies. The company raised $110M in a Series C to extend the platform's capabilities, expand its European and Asia-Pacific presence, and grow its commercial team. The funding will support product development, commercialization efforts, and broader geographic expansion. Aetion is based in New York City. Aetion provides the Aetion Evidence Platform®, which analyzes real-world data to produce transparent, rapid, and scientifically validated answers on the safety, effectiveness, and value of medical products across the product life cycle. The platform serves manufacturers, purchasers, and regulators of medical technologies as well as payers and biopharma companies. Led by CEO Carolyn Magill, the company positions itself to align biopharma, regulators, HTA bodies, and payers around assessment of medications. The recent financing will fund expansion of the Aetion Evidence Platform® capabilities and advance a global effort to establish standards for real‑world evidence (RWE). Financially, the company has raised $82M in its Series B (after the extension) and $94M in total funding since its 2015 commercial launch. Aetion offers the Aetion Evidence Platform™, which analyzes real-world data to produce scientifically validated answers on treatments, costs, and outcomes. The platform is used by eight of the top 15 global biopharma firms, payers, academic institutions, the U.S. FDA and other major international regulatory bodies. Founded in 2015 by Harvard Medical School faculty and led by CEO Carolyn Magill, the company has pursued partnerships to demonstrate the value of real-world evidence. In 2018 Aetion began the DUPLICATE study with the FDA to recreate 30 randomized clinical trials using real-world evidence; the three-year study is referenced in the FDA’s RWE Framework. The company plans to use new funding to strengthen its platform, extend therapeutic-area intelligence, support outcomes-based contracting for payers, and advance global acceptance of real-world evidence standards. Aetion has raised $77 million to date and capped its Series B at $63 million after the latest investment. Aetion provides a software solution that leverages real-world data to evaluate the safety, effectiveness, and value of medications. Biopharma companies use the platform to demonstrate to payers and regulators which medications will best serve their populations, supporting care access and appropriateness. For payers, Aetion enables identification of therapies that are clinically effective and cost-effective, informing formulary and plan design to boost patient outcomes and curb premium hikes. The company plans to use the Series B proceeds to further build out its platform to support specific complex therapeutic areas and to expand its team of biopharma and pharmacy benefit design experts. Led by CEO Carolyn Magill and based in New York City, Aetion has raised $50m to date, including the $36.4m Series B. Aetion provides payer, provider, biopharma, and medical device customers with a platform that combines science and computing technology to generate insights into the clinical and financial status of populations. The platform enables customers to measure and compare the effectiveness and value of treatments and provider practices and to realize value-based contracting. The company is led by co-founder Jeremy A. Rassen, Sc.D., (president and chief scientific officer) and co-founder Sebastian Schneeweiss, M.D., Sc.D., (science lead and professor at Harvard Medical School). Aetion is based in New York City. The company secured $11.2M in Series A funding on March 20, 2017. It intends to use the funds to extend its platform's capabilities and to expand and commercialize its solutions.